Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. https://www.creative-peptides.com/product/romidepsin-item-10-101-186-33671.html

Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in industry and research area. Creative Peptides is staffed by scientific teams with experts in the field of peptide technology, antibodies and synthetic chemistry. Our extensive expertise is translated into high quality products and world-class services to ensure the maximum satisfaction of the customers.